Due to the impact of the national pricing negotiations on targeted anti-cancer drugs, the monthly DDDc decreased significantly for gefitinib, bevacizumab, and recombinant human endostatin (P < 0.001, P < 0.001, P < 0.001). This evidence concerns the gene COL18A1 and cancer.